Searched for
CIPLA SA
Cipla shares slide 5% after temporary halt in key drug manufacturingCipla shares fell sharply on Friday after a halt in Lanreotide Injection production due to USFDA observations at its Greek partner. Supply ...- Cipla Q1 results preview: PAT may grow 6.5-14% YoY, up to 10% growth seen in revenueCipla reported Q1FY25 net profit expected between Rs 1,061-1,135 crore, with YoY growth of 6.5%-14%. Revenue estimated at Rs 6,749-6,879 cr...
- Cipla shares surge over 6% post Q4 results. Should you buy or sell?Meanwhile, EBITDA for the quarter under review increased 13% YoY to Rs 1,316 crore as against 1166 crore in the last year period.
- Cipla Q4 Results Preview: Profit may rise up to 71% YoY on healthy operationsCipla Q4 Results Preview: As per the combined projections of four brokerages, there's a possibility of the net profit for the fourth quarte...
- Outlook on healthcare sector; Cipla & Sun Pharma could give 15-20% returnANDA approval rate has been on a steady rise post-COVID, from the low of 540 in CY21 to ~700+ annual approvals in CY23E, backed by a reduct...
- Hot Stocks: Brokerage view on Fusion Micro, Tata Steel, AU Small Finance Bank and CiplaInCred initiated coverage on Fusion Micro with an ADD rating and a target of Rs 800. Robust growth was led by deepening penetration and div...
- Cipla shares jump 9% after Q1 profit soars 45% YoY to Rs 996 crore. Should you buy, sell or hold?In morning session, the scrip was trading 8.5% higher at Rs 1.160 on BSE. Meanwhile, in the last one year, it has surged 19%.
- Brokerages see up to 20% upside in Cipla post Q1 results; time to buy?Cipla is on track to launch key products, such as gAdvair, gAbraxane, gRevlimid and three peptide products over FY23-24, it said, adding th...
- Cipla Q4 Results: Profit falls 12.4% YoY to Rs 362 cr, misses estimatesThe total revenue from operations was Rs 5,260.33 crore, up 14.19 per cent from Rs 4,606.45 crore the company reported in the year-ago quar...
- After Market: R-Adag stocks bleed, Jet at all-time low; Yes Bank hits 5-year lowRupee’s weakness against the US dollar also influenced market mood.
- Cipla shares flat ahead of Q3 results: What to expectNirmal Bang Securities sees 12.70 per cent year-on-year rise in net profit for Cipla in Q3 FY19 on 7 per cent.
- Buy Cipla; target Rs 605: HDFC SecuritiesBuy Cipla Ltd. at a price target of Rs 605.
- Cipla appoints Naina Lal Kidwai as an independent directorIndia's third largest drug maker Cipla has appointed Naina Lal Kidwai on its board as an independent director.
- Pharma stocks rally after SC's Novartis verdict; analysts positive on DRL, Cipla, NatcoPharma stocks surged 2-5 per cent after the Supreme Court dismissed Novartis AG's plea for getting its blood cancer drug patented in India.
- Doubts over Cipla India's takeover bid of S African unitAnalysts had expected shareholders to support the 100% takeover offer, but are now doubtful after questioning the reasons for Cipla SA want...
- Brokers’ Call: Espirito puts a buy on CiplaEspirito Santo Securities has given a ‘Buy’ rating on Cipla with a fair value of Rs 440.
- Aanjaneya Lifecare FY-11 net surges two-fold to Rs 36 croreNet sales of the company for the year ended March 31,2011 rose to Rs 320.25 crore from Rs 161.67 crore during the same period previous fisc...
- Aanjaneya Lifecare gets Rs 60 cr order for making cough syrupBulk drug maker said it has received orders worth Rs 60 cr from Wockhardt and Cipla, for manufacturing cough syrup 'Recodex'.
- Cipla looks to acquire 25% stake in South African coCipla said it could take a decision to buy stake of up to 25 per cent in South Africa-based, Cipla Medpro in next board meeting. Cipla Medp...
- Ranbaxy, Cipla among Indian cos in race for $200 mn drug dealRanbaxy Laboratories, Cipla and Aurobindo Pharmaceuticals are submitting bids for the $200 mn South African govt tender to supply anti-HIV ...
Load More
